NCT04076059 2026-04-17
China ARCHES
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT03395197 2026-04-07
TALAPRO-2
Pfizer
Phase 3 Active not recruiting
NCT04191096 2026-03-20
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02522715 2026-02-24
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Active not recruiting
NCT02749903 2026-02-11
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03246347 2026-01-23
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT04647526 2026-01-13
SPLASH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT02312557 2025-12-03
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03834493 2025-07-18
KEYNOTE-641
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02955394 2025-07-09
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT02319837 2025-07-08
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting